| Literature DB >> 29743351 |
Jan Strnadel1,2, Cassiano Carromeu3, Cedric Bardy4,5, Michael Navarro1, Oleksandr Platoshyn1, Andreas N Glud1, Silvia Marsala1, Jozef Kafka1, Atsushi Miyanohara1,6, Tomohisa Kato7, Takahiro Tadokoro1, Michael P Hefferan1, Kota Kamizato1, Tetsuya Yoshizumi1, Stefan Juhas8, Jana Juhasova8, Chak-Sum Ho9, Taba Kheradmand9, PeiXi Chen1, Dasa Bohaciakova1,10, Marian Hruska-Plochan1,11, Andrew J Todd12, Shawn P Driscoll13, Thomas D Glenn13, Samuel L Pfaff13, Jiri Klima8, Joseph Ciacci14, Eric Curtis14, Fred H Gage4, Jack Bui15, Kazuhiko Yamada16, Alysson R Muotri3, Martin Marsala17,18.
Abstract
The use of autologous (or syngeneic) cells derived from induced pluripotent stem cells (iPSCs) holds great promise for future clinical use in a wide range of diseases and injuries. It is expected that cell replacement therapies using autologous cells would forego the need for immunosuppression, otherwise required in allogeneic transplantations. However, recent studies have shown the unexpected immune rejection of undifferentiated autologous mouse iPSCs after transplantation. Whether similar immunogenic properties are maintained in iPSC-derived lineage-committed cells (such as neural precursors) is relatively unknown. We demonstrate that syngeneic porcine iPSC-derived neural precursor cell (NPC) transplantation to the spinal cord in the absence of immunosuppression is associated with long-term survival and neuronal and glial differentiation. No tumor formation was noted. Similar cell engraftment and differentiation were shown in spinally injured transiently immunosuppressed swine leukocyte antigen (SLA)-mismatched allogeneic pigs. These data demonstrate that iPSC-NPCs can be grafted into syngeneic recipients in the absence of immunosuppression and that temporary immunosuppression is sufficient to induce long-term immune tolerance after NPC engraftment into spinally injured allogeneic recipients. Collectively, our results show that iPSC-NPCs represent an alternative source of transplantable NPCs for the treatment of a variety of disorders affecting the spinal cord, including trauma, ischemia, or amyotrophic lateral sclerosis.Entities:
Mesh:
Year: 2018 PMID: 29743351 DOI: 10.1126/scitranslmed.aam6651
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956